CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 77 enrolled
Drug / intervention
CoA-Z +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04182763
NCT04182763N/ACompleted
CompareCT.gov

A Phase 2 Study of a Vitamin Metabolite for PKAN

Oregon Health and Science University·interventional·Posted Dec 2, 2019·Updated Oct 29, 2025

In Brief

A clinical study evaluating CoA-Z and Placebo for Pantothenate Kinase-Associated Neurodegeneration. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The purpose of this study is to learn more about how people with the condition pantothenate kinase-associated neurodegeneration (PKAN) respond to a specialized study product. We are hoping to find out if the study product is safe, what effects-good and bad-the study product causes, and whether the study product changes certain measures of disease in PKAN.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPantothenate Kinase-Associated Neurodegeneration
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Washington State University, Oregon State University, Spoonbill Foundation, Spoonbill

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 2, 2019
Enrollment StartDec 4, 2019
Primary CompletionSep 1, 2024
Study CompletionJan 1, 2025
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 6.6 years ago

Interventions

CoA-Zother

People with PKAN lack a chemical to process or metabolize a certain vitamin in the brain. CoA-Z is designed to bypass this metabolic defect that causes PKAN.

Placeboother

The placebo is a strawberry-flavored syrup that looks and tastes like CoA-Z but has no active CoA-Z in it.